发布求助
文献互助 智能选刊 最新文献

Clinical advances in hematology & oncology : H&O最新文献

筛选
英文 中文
Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer. 曲妥珠单抗难治性her2阳性转移性乳腺癌的治疗
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Sara Hurvitz
{"title":"Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer.","authors":"Sara Hurvitz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"260-2"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32488747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implementation of next-generation sequencing. 新一代测序的临床实施。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Richard D Press
{"title":"Clinical implementation of next-generation sequencing.","authors":"Richard D Press","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"263-5"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32488748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. 选择性抑制Bcl-2治疗慢性淋巴细胞白血病和非霍奇金淋巴瘤。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Samuel Y Ng, Matthew S Davids
{"title":"Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.","authors":"Samuel Y Ng,&nbsp;Matthew S Davids","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>ABT-199, a second-generation BH3 mimetic, is an orally bioavailable, small molecule inhibitor that selectively targets B-cell lymphoma/leukemia 2 (Bcl-2). Bcl-2 is a key protein that inhibits the intrinsic mitochondrial pathway of apoptosis. First-generation BH3 mimetics such as navitoclax (ABT-263) had a broad range of inhibitory activity against Bcl-2 family members, including Bcl-2, Bcl-XL, and Bcl-w. This drug demonstrated antitumor activity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL); however, on-target Bcl-XL inhibition led to dose-dependent thrombocytopenia and posed a barrier to maximizing the activity of this agent. Through an elegant reengineering of navitoclax, ABT-199 was developed as a Bcl-2-selective small molecule inhibitor. In preclinical studies, ABT-199 was shown to have greater than 100-fold selectivity for Bcl-2 over Bcl-XL. This selectivity has been consistent with the early results of the ongoing phase 1 clinical trial of ABT-199 in which the drug has demonstrated high rates of activity in relapsed/refractory CLL and NHL without dose-dependent thrombocytopenia. On-target tumor lysis syndrome (TLS) has been observed in a subset of patients treated with ABT-199, but changes in initial dosing and stepwise dose escalation have now been implemented to mitigate this risk. Ongoing correlative studies are being performed to help identify patients with the highest chance of response and the greatest risk for TLS.</p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"224-9"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32487111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can radiotherapy be omitted in patients with localized hodgkin lymphoma? 局部霍奇金淋巴瘤患者是否可以省略放疗?
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
{"title":"Can radiotherapy be omitted in patients with localized hodgkin lymphoma?","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"247"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32488746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients at high risk for recurrence need radiotherapy. 复发风险高的患者需要放疗。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Eli Glatstein, John P Plastaras
{"title":"Patients at high risk for recurrence need radiotherapy.","authors":"Eli Glatstein,&nbsp;John P Plastaras","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"247, 250-1"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32594408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel treatments in acute lymphocytic leukemia. 急性淋巴细胞白血病的新疗法。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Anthony S Stein
{"title":"Novel treatments in acute lymphocytic leukemia.","authors":"Anthony S Stein","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"212-4"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32487109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burnout. 倦怠。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Bruce D Cheson
{"title":"Burnout.","authors":"Bruce D Cheson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"208"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32487108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. 非典型溶血性尿毒症综合征:补体途径基因突变的作用分析。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Ilene C Weitz
{"title":"Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis.","authors":"Ilene C Weitz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"266-8"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32488749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma. 贝伐单抗在非结直肠胃肠道恶性肿瘤中的发展:胃食管癌、胰腺癌和肝细胞癌。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
Manish A Shah
{"title":"The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.","authors":"Manish A Shah","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bevacizumab (Avastin, Genentech) is a potent inhibitor of vascular endothelial growth factor A that has demonstrated modest antitumor activity across a broad range of malignancies when combined with chemotherapy. In colorectal cancer, bevacizumab in combination with chemotherapy is a standard of care for first-line therapy, and is used as second-line therapy in both bevacizumab-naive patients and those who have progressed on first-line therapy containing bevacizumab. Bevacizumab has been examined in nongastrointestinal malignancies as well. Across these multiple studies, virtually all of which demonstrate some improvement in progression-free survival, the combination of chemotherapy and bevacizumab has not led to a significant improvement in overall survival. Unfortunately, the addition of bevacizumab to chemotherapy translates into only slight improvement in overall survival in a few malignancies, including colorectal cancer. In this review, we highlight the development of bevacizumab in noncolorectal gastrointestinal malignancies, and potential future directions in antiangiogenic drug development. </p>","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"239-46"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32488745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy should be omitted in most patients. 大多数患者应避免放疗。
IF 1
Clinical advances in hematology & oncology : H&O Pub Date : 2014-04-01
David J Straus
{"title":"Radiotherapy should be omitted in most patients.","authors":"David J Straus","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"247-9"},"PeriodicalIF":1.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32594407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书